FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

被引:351
作者
Stintzing, Sebastian [1 ,3 ]
Modest, Dominik P. [1 ,3 ]
Rossius, Lisa [1 ]
Lerch, Markus M. [4 ]
von Weikersthal, Ludwig Fischer [5 ]
Decker, Thomas [6 ]
Kiani, Alexander [7 ]
Vehling-Kaiser, Ursula [8 ]
Al-Batran, Salah-Eddin [9 ]
Heintges, Tobias [10 ]
Lerchenmueller, Christian [11 ]
Kahl, Christoph [12 ]
Seipelt, Gernot [13 ,14 ]
Kullmann, Frank [15 ]
Stauch, Martina [16 ]
Scheithauer, Werner [17 ]
Held, Swantje [18 ]
Giessen-Jung, Clemens [1 ]
Moehler, Markus [19 ]
Jagenburg, Andreas [20 ]
Kirchner, Thomas [2 ,3 ]
Jung, Andreas [2 ,3 ]
Heinemann, Volker [1 ,3 ]
机构
[1] Univ Munich, Dept Hematol & Oncol, Munich, Germany
[2] Univ Munich, Inst Pathol, Munich, Germany
[3] German Canc Res Ctr, German Canc Consortium, DKTK, Heidelberg, Germany
[4] Univ Med Greifswald, Klin & Poliklin Innere Med A, Greifswald, Germany
[5] St Marien GmbH, MVZ Gesundheitszentrum, Amberg, Germany
[6] Studienzentrum Onkol Ravensburg, Ravensburg, Germany
[7] Klinikum Bayreuth GmbH, Bayreuth, Germany
[8] Praxis Hamatol Onkol Palliat Med Tagesklin, Landshut, Germany
[9] Krankenhaus NW Frankfurt, Med Klin Onkol 2, Frankfurt, Germany
[10] Lukaskrankenhaus Neuss, Neuss, Germany
[11] Gemeinschaftspraxis Hamatol & Onkol, Munster, Germany
[12] Stadt Klinikum Magdeburg, Hamatol Onkol, Magdeburg, Germany
[13] Onkol Schwerpunktpraxis, Bad Soden, Germany
[14] Tagesklinik, Bad Soden, Germany
[15] Klinikum Weiden, Med Klin 1, Weiden, Germany
[16] Praxis Hamatol & Internist Onkol, Kronach, Germany
[17] Klin Abt Onkol, Univ Klin Innere Med 1, Vienna, Austria
[18] ClinAssess GmbH, Leverkusen, Germany
[19] Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 1, Mainz, Germany
[20] Radiol Consulting GmbH, Leverkusen, Germany
关键词
1ST-LINE TREATMENT; SOLID TUMORS; SHRINKAGE; PREDICT; SURVIVAL; DEPTH;
D O I
10.1016/S1470-2045(16)30269-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer. The same study also reported an exploratory analysis of a subgroup of patients with tumours that were wild-type at other RAS genes (KRAS and NRAS exons 2-4). We report here efficacy results for the FIRE-3 final RAS (KRAS/NRAS, exons 2-4) wild-type subgroup. Moreover, new metrics of tumour dynamics were explored during a centralised radiological review to investigate how FOLFIRI plus cetuximab conferred overall survival benefit in the absence of differences in investigator-assessed objective responses and progression-free survival. Methods FIRE-3 was a randomised phase 3 trial comparing FOLFIRI plus cetuximab with FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal cancer. The primary endpoint of the FIRE-3 study was the proportion of patients achieving an objective response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 in the intention-to-treat population. A centralised radiological review of CT scans was done in a post-hoc analysis to assess objective response according to RECIST 1.1, early tumour shrinkage, depth of response, duration of response, and time to response in the final RAS wild-type subgroup. Comparisons between treatment groups with respect to objective response rate and early tumour shrinkage were made using Fisher's exact test (two-sided), while differences in depth of response were investigated with a two-sided Wilcoxon test. This trial is registered at ClinicalTrials. gov, number NCT00433927. Findings In the final RAS wild-type population (n=400), median overall survival was better in the FOLFIRI plus cetuximab group than the FOLFIRI plus bevacizumab group (33.1 months [95% CI 24.5-39.4] vs 25.0 months [23.0-28.1]; hazard ratio 0.70 [0.54-0.90]; p=0.0059), although investigator-assessed objective response and progression-free survival were comparable between treatment groups. Centralised radiological review of CT-assessable patients (n=330) showed that the proportion of patients achieving an objective response (113 of 157, 72.0% [95% CI 64.3-78.8] vs 97 of 173, 56.1% [48.3-63.6]; p= 0.0029), frequency of early tumour shrinkage (107 of 157, 68.2% [60.3-75.4] vs 85 of 173, 49.1% [41.5-56.8]; p= 0.0005), and median depth of response (-48.9% [-54.3 to -42.0] vs-32.3% [-38.2 to -29.2]; p<0.0001) were signifi cantly better in extended RAS wild-type patients receiving FOLFIRI plus cetuximab versus those receiving FOLFIRI plus bevacizumab. No differences in duration of response and time to response were observed between treatment groups. Interpretation This analysis provides a new framework that connects alternative metrics of response to overall survival. Superior response-related outcome parameters, such as early tumour shrinkage and depth of response, obtained by centralised radiological review correlated with the overall survival benefit conferred by FOLFIRI plus cetuximab compared with FOLFIRI plus bevacizumab in the extended RAS wild-type subgroup. Funding Merck KGaA and Pfizer.
引用
收藏
页码:1426 / 1434
页数:9
相关论文
共 21 条
[1]   Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer [J].
Claret, Laurent ;
Gupta, Manish ;
Han, Kelong ;
Joshi, Amita ;
Sarapa, Nenad ;
He, Jing ;
Powell, Bob ;
Bruno, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) :2110-2114
[2]   Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics [J].
Claret, Laurent ;
Girard, Pascal ;
Hoff, Paulo M. ;
Van Cutsem, Eric ;
Zuideveld, Klaas P. ;
Jorga, Karin ;
Fagerberg, Jan ;
Bruno, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4103-4108
[3]   Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest [J].
Cremolini, C. ;
Loupakis, F. ;
Antoniotti, C. ;
Lonardi, S. ;
Masi, G. ;
Salvatore, L. ;
Cortesi, E. ;
Tomasello, G. ;
Spadi, R. ;
Zaniboni, A. ;
Tonini, G. ;
Barone, C. ;
Vitello, S. ;
Longarini, R. ;
Bonetti, A. ;
D'Amico, M. ;
Di Donato, S. ;
Granetto, C. ;
Boni, L. ;
Falcone, A. .
ANNALS OF ONCOLOGY, 2015, 26 (06) :1188-1194
[4]   Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Peeters, Marc ;
Koukakis, Reija ;
Terwey, Jan-Henrik ;
Tabernero, Josep .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) :1231-1242
[5]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[6]   Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial [J].
Giessen, Clemens ;
Laubender, Ruediger P. ;
von Weikersthal, Ludwig Fischer ;
Schalhorn, Andreas ;
Modest, Dominik P. ;
Stintzing, Sebastian ;
Haas, Michael ;
Mansmann, Ulrich R. ;
Heinemann, Volker .
CANCER SCIENCE, 2013, 104 (06) :718-724
[7]   Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC) [J].
Heinemann, Volker ;
Stintzing, Sebastian ;
Modest, Dominik P. ;
Giessen-Jung, Clemens ;
Michl, Marlies ;
Mansmann, Ulrich R. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (14) :1927-1936
[8]   FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].
Heinemann, Volker ;
von Weikersthal, Ludwig Fischer ;
Decker, Thomas ;
Kiani, Alexander ;
Vehling-Kaiser, Ursula ;
Al-Batran, Salah-Eddin ;
Heintges, Tobias ;
Lerchenmueller, Christian ;
Kahl, Christoph ;
Seipelt, Gernot ;
Kullmann, Frank ;
Stauch, Martina ;
Scheithauer, Werner ;
Hielscher, Joerg ;
Scholz, Michael ;
Mueller, Sebastian ;
Link, Hartmut ;
Niederle, Norbert ;
Rost, Andreas ;
Hoeffkes, Heinz-Gert ;
Moehler, Markus ;
Lindig, Reinhard U. ;
Modest, Dominik P. ;
Rossius, Lisa ;
Kirchner, Thomas ;
Jung, Andreas ;
Stintzing, Sebastian .
LANCET ONCOLOGY, 2014, 15 (10) :1065-1075
[9]   Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal Cancer [J].
Jang, H. J. ;
Kim, B. C. ;
Kim, H. S. ;
Kim, J. H. ;
Song, H. H. ;
Kim, J. B. ;
Park, J. J. ;
Yoon, S. N. ;
Woo, J. Y. ;
Zang, D. Y. .
ONCOLOGY, 2014, 86 (02) :117-121
[10]   Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials [J].
Khattak, Muhammad A. ;
Martin, Hilary ;
Davidson, Andrew ;
Phillips, Michael .
CLINICAL COLORECTAL CANCER, 2015, 14 (02) :81-90